The Asia Pacific Bronchodilators Market would witness market growth of 4.6% CAGR during the forecast period (2022-2028).
The bronchodilators come in two forms which are short-acting and long-acting bronchodilators. Short-acting bronchodilators stop or provide relief from sudden symptoms of asthma quickly. They are effective for three to six hours. They are also known as a rescue inhaler. Inhalers are canisters of medicine in a plastic holder with a mouthpiece.
The steps theory in managing reversible lung diseases like asthma incorporates long- and short-acting bronchodilators. Those with intermittent asthma should get a short-acting bronchodilator like albuterol as per requirement. For more symptomatic disease, adding a low-dose inhaled corticosteroid is generally the next step, followed by adding a long-acting bronchodilator with the inhaled steroid. The increment in the aggressive treatment should differ from those who specialize in allergy and asthma treatment.
After achieving control, the patient can consult with their doctor to change these medications to a smaller dose with fewer adverse effects. Failure to control symptoms with short or long-acting corticosteroids and bronchodilators can cause irreversible lung injury. Frequent monitoring through pulmonary function tests and peak airway flow is essential for the success of the treatment.
China is the biggest consumer and producer of tobacco globally. There are more than 300 million smokers in China, which is around one-third of the world’s total. In China, more than half of adult men are tobacco smokers. About one in every three cigarettes smoked is in China. In addition, over 700 million non-smokers in China, including 180 million children, are exposed to second-hand smoke at least once a day a week. The high level of tobacco consumption will increase the number of respiratory cases and the utilization of bronchodilators medication, thus propelling the market growth in the region.
The China market dominated the Asia Pacific Bronchodilators Market by Country in 2021; thereby, achieving a market value of $1,709.1 million by 2028. The Japan market is registering a CAGR of 4% during (2022 - 2028). Additionally, The India market would showcase a CAGR of 5.2% during (2022 - 2028).
Based on Drug Class, the market is segmented into Beta-Adrenergic, Xanthine Derivatives, and Anticholinergic. Based on Route of Administration, the market is segmented into Nasal (Inhalable), Oral, and Injectable. Based on Disease, the market is segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glenmark Pharmaceuticals Limited, Merck & Co., Inc., GlaxoSmithKline PLC, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Cipla Limited, Viatris, Inc., Novartis AG, Boehringer Ingelheim International GmbH and Sun Pharmaceutical Industries Ltd.
The bronchodilators come in two forms which are short-acting and long-acting bronchodilators. Short-acting bronchodilators stop or provide relief from sudden symptoms of asthma quickly. They are effective for three to six hours. They are also known as a rescue inhaler. Inhalers are canisters of medicine in a plastic holder with a mouthpiece.
The steps theory in managing reversible lung diseases like asthma incorporates long- and short-acting bronchodilators. Those with intermittent asthma should get a short-acting bronchodilator like albuterol as per requirement. For more symptomatic disease, adding a low-dose inhaled corticosteroid is generally the next step, followed by adding a long-acting bronchodilator with the inhaled steroid. The increment in the aggressive treatment should differ from those who specialize in allergy and asthma treatment.
After achieving control, the patient can consult with their doctor to change these medications to a smaller dose with fewer adverse effects. Failure to control symptoms with short or long-acting corticosteroids and bronchodilators can cause irreversible lung injury. Frequent monitoring through pulmonary function tests and peak airway flow is essential for the success of the treatment.
China is the biggest consumer and producer of tobacco globally. There are more than 300 million smokers in China, which is around one-third of the world’s total. In China, more than half of adult men are tobacco smokers. About one in every three cigarettes smoked is in China. In addition, over 700 million non-smokers in China, including 180 million children, are exposed to second-hand smoke at least once a day a week. The high level of tobacco consumption will increase the number of respiratory cases and the utilization of bronchodilators medication, thus propelling the market growth in the region.
The China market dominated the Asia Pacific Bronchodilators Market by Country in 2021; thereby, achieving a market value of $1,709.1 million by 2028. The Japan market is registering a CAGR of 4% during (2022 - 2028). Additionally, The India market would showcase a CAGR of 5.2% during (2022 - 2028).
Based on Drug Class, the market is segmented into Beta-Adrenergic, Xanthine Derivatives, and Anticholinergic. Based on Route of Administration, the market is segmented into Nasal (Inhalable), Oral, and Injectable. Based on Disease, the market is segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glenmark Pharmaceuticals Limited, Merck & Co., Inc., GlaxoSmithKline PLC, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Cipla Limited, Viatris, Inc., Novartis AG, Boehringer Ingelheim International GmbH and Sun Pharmaceutical Industries Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Drug Class
- Beta-Adrenergic
- Xanthine Derivatives
- Anticholinergic
By Route of Administration
- Nasal (Inhalable)
- Oral
- Injectable
By Disease
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Glenmark Pharmaceuticals Limited
- Merck & Co., Inc
- GlaxoSmithKline PLC
- AstraZeneca PLC
- Teva Pharmaceuticals Industries Ltd
- Cipla Limited
- Viatris, Inc
- Novartis AG
- Boehringer Ingelheim International GmbH
- Sun Pharmaceutical Industries Ltd
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Bronchodilators Market, by Drug Class
1.4.2 Asia Pacific Bronchodilators Market, by Route of Administration
1.4.3 Asia Pacific Bronchodilators Market, by Disease
1.4.4 Asia Pacific Bronchodilators Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Bronchodilators Market by Drug Class
3.1 Asia Pacific Beta-Adrenergic Market by Country
3.2 Asia Pacific Xanthine Derivatives Market by Country
3.3 Asia Pacific Anticholinergic Market by Country
Chapter 4. Asia Pacific Bronchodilators Market by Route of Administration
4.1 Asia Pacific Nasal (Inhalable) Market by Country
4.2 Asia Pacific Oral Market by Country
4.3 Asia Pacific Injectable Market by Country
Chapter 5. Asia Pacific Bronchodilators Market by Disease
5.1 Asia Pacific Asthma Market by Country
5.2 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Market by Country
5.3 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific Bronchodilators Market by Country
6.1 China Bronchodilators Market
6.1.1 China Bronchodilators Market by Drug Class
6.1.2 China Bronchodilators Market by Route of Administration
6.1.3 China Bronchodilators Market by Disease
6.2 Japan Bronchodilators Market
6.2.1 Japan Bronchodilators Market by Drug Class
6.2.2 Japan Bronchodilators Market by Route of Administration
6.2.3 Japan Bronchodilators Market by Disease
6.3 India Bronchodilators Market
6.3.1 India Bronchodilators Market by Drug Class
6.3.2 India Bronchodilators Market by Route of Administration
6.3.3 India Bronchodilators Market by Disease
6.4 South Korea Bronchodilators Market
6.4.1 South Korea Bronchodilators Market by Drug Class
6.4.2 South Korea Bronchodilators Market by Route of Administration
6.4.3 South Korea Bronchodilators Market by Disease
6.5 Singapore Bronchodilators Market
6.5.1 Singapore Bronchodilators Market by Drug Class
6.5.2 Singapore Bronchodilators Market by Route of Administration
6.5.3 Singapore Bronchodilators Market by Disease
6.6 Malaysia Bronchodilators Market
6.6.1 Malaysia Bronchodilators Market by Drug Class
6.6.2 Malaysia Bronchodilators Market by Route of Administration
6.6.3 Malaysia Bronchodilators Market by Disease
6.7 Rest of Asia Pacific Bronchodilators Market
6.7.1 Rest of Asia Pacific Bronchodilators Market by Drug Class
6.7.2 Rest of Asia Pacific Bronchodilators Market by Route of Administration
6.7.3 Rest of Asia Pacific Bronchodilators Market by Disease
Chapter 7. Company Profiles
7.1 Glenmark Pharmaceuticals Limited
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Research & Development Expenses
7.1.4 Recent strategies and developments:
7.1.4.1 Product Launches and Product Expansions:
7.2 Merck & Co., Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expenses
7.3 GlaxoSmithKline PLC
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.4 AstraZeneca PLC
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.5 Teva Pharmaceutical Industries Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.6 Cipla Limited
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.7 Viatris, Inc. (Mylan N.V.)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 Novartis AG
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Boehringer Ingelheim International Gmbh
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional & Segmental Analysis
7.9.4 Research & Development Expenses
7.10. Sun Pharmaceutical Industries Ltd.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional & Segmental Analysis
7.10.4 Research & Development Expenses
Companies Mentioned
- Glenmark Pharmaceuticals Limited
- Merck & Co., Inc.
- GlaxoSmithKline PLC
- AstraZeneca PLC
- Teva Pharmaceuticals Industries Ltd.
- Cipla Limited
- Viatris, Inc.
- Novartis AG
- Boehringer Ingelheim International GmbH
- Sun Pharmaceutical Industries Ltd.
Methodology
LOADING...
